Cargando…

Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis

Objectives To examine the safety and effectiveness of cobalt-chromium everolimus eluting stents compared with bare metal stents. Design Individual patient data meta-analysis of randomised controlled trials. Cox proportional regression models stratified by trial, containing random effects, were used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valgimigli, Marco, Sabaté, Manel, Kaiser, Christoph, Brugaletta, Salvatore, de la Torre Hernandez, Jose Maria, Galatius, Soeren, Cequier, Angel, Eberli, Franz, de Belder, Adam, Serruys, Patrick W, Ferrante, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220288/ https://www.ncbi.nlm.nih.gov/pubmed/25378023 http://dx.doi.org/10.1136/bmj.g6427

Ejemplares similares

Cost‐effectiveness of percutaneous coronary intervention with cobalt‐chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta‐analysis of randomized trials
por: Ferko, Nicole, et al.
Publicado: (2016)

Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial
por: Schur, Nadine, et al.
Publicado: (2018)

Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans
por: Mori, Hiroyoshi, et al.
Publicado: (2017)

Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial
por: Sabaté, Manel, et al.
Publicado: (2016)

Drug‐Eluting or Bare‐Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization
por: Piccolo, Raffaele, et al.
Publicado: (2021)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial
por: Natsuaki, Masahiro, et al.
Publicado: (2015)

Stent Fracture after Everolimus-Eluting Stent Implantation
por: Almasood, Ali S., et al.
Publicado: (2011)

Early definite stent thrombosis with everolimus-eluting stents
por: Naito, Ryo, et al.
Publicado: (2015)

A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
por: Bennett, Johan, et al.
Publicado: (2013)

Everolimus-eluting stents in interventional cardiology
por: Townsend, Jacob C, et al.
Publicado: (2012)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

An Interesting Case and Literature Review of a Coronary Stent Fracture in a Current Generation Platinum Chromium Everolimus-Eluting Stent
por: Aung, Sammy San Myint, et al.
Publicado: (2018)

Comparison of drug-eluting and bare metal stents for extracranial vertebral artery stenting
por: Maciejewski, Damian R., et al.
Publicado: (2019)

Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents
por: Iglesias, Juan F., et al.
Publicado: (2019)

Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent
por: Dalos, Daniel, et al.
Publicado: (2016)

Identification of independent risk factors for restenosis following bare-metal stent implantation: Role of bare-metal stents in the era of drug-eluting stents
por: PARK, CHANG-BUM, et al.
Publicado: (2013)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Everolimus-eluting stents: update on current clinical studies
por: Allocco, Dominic J, et al.
Publicado: (2011)

Long‐Term Results After Drug‐Eluting Versus Bare‐Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial
por: Fahrni, Gregor, et al.
Publicado: (2020)

Comparison of bare metal stent and paclitaxel-eluting stent using a novel rat aorta stent model
por: Kwon, Jin Sook, et al.
Publicado: (2011)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
por: Kakizaki, Ryota, et al.
Publicado: (2020)

Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents
por: Sharma, Raghav, et al.
Publicado: (2022)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
por: Whitbeck, Matthew G., et al.
Publicado: (2013)

Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
por: Stettler, Christoph, et al.
Publicado: (2008)

Ultrathin Strut Biodegradable Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent for Percutaneous Coronary Revascularization: 2‐Year Results of the BIOSCIENCE Trial
por: Zbinden, Rainer, et al.
Publicado: (2016)

Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial
por: Arroyo, Diego A, et al.
Publicado: (2018)

One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2016)

Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta‑analysis
por: Yin, Juntao, et al.
Publicado: (2023)

Midterm Clinical Impacts of Biodegradable Polymer Everolimus-Eluting Stents Compared with Durable Polymer Everolimus-Eluting Stents: A 3-Year Propensity-Matched Study
por: Matsuda, Hiroaki, et al.
Publicado: (2020)

Lesion Length Impacts Long Term Outcomes of Drug-Eluting Stents and Bare Metal Stents Differently
por: Chang, Shang-Hung, et al.
Publicado: (2013)

Identification of functional modules induced by bare-metal stents and paclitaxel-eluting stents in coronary heart disease
por: Tang, Zhaobin, et al.
Publicado: (2018)

Vascular Responses to First-Generation Sirolimus-Eluting Stents and Bare-Metal Stents Beyond 10 Years
por: Hada, Masahiro, et al.
Publicado: (2021)

Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents
por: Ahmed, Talha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3cjb5khn757nqs2u16rd9v3b0c